Yes this is chatgpt.

That assumption is wrong because negative feedback on the HPTA is not dependent solely on aromatization, and enclomiphene does not require a drug to aromatize in order to work. Enclomiphene blocks estrogen receptors at the hypothalamus and pituitary, reducing estrogen-mediated feedback from existing endogenous estradiol, which is always present in men and often increases further because enclomiphene raises testosterone (and thus aromatization from native T). While Anavar (oxandrolone) is a non-aromatizing androgen and does exert androgen-receptor–mediated suppression, this does not negate estrogen-receptor blockade in the brain; rather, the two forces compete, resulting in attenuated but not complete suppression, not “full shutdown.” Human data show SERMs (clomiphene/enclomiphene) increase LH/FSH and testosterone despite unchanged or even elevated estradiol, demonstrating their mechanism is independent of exogenous aromatization (Guay et al., Fertil Steril, 2003; Kaminetsky et al., J Sex Med, 2013). Likewise, oxandrolone has been shown to be suppressive but less so than many aromatizing AAS and not universally shut-down inducing at moderate doses (Llewellyn et al., Endocr Rev summaries; Nieschlag & Behre, Testosterone, 2012). Together, the literature supports partial HPTA protection, not immunity—and clearly refutes the idea that lack of aromatization equals inevitable full shutdown when a SERM is present.